Andrew J. Davis
Andrew J. Davis has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Allan Hallett
Novartis Institutes for Biomedical Research, 5 Gower Place, London WC1E 6BS, U.K., and Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland
4 shared publicationsClare Davis
Novartis Institutes for Biomedical Research, 5 Gower Place, London WC1E 6BS, U.K., and Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland
4 shared publicationsMohammed Yaqoob
Novartis Institutes for BioMedical Research, 5 Gower Place, London WC1E 6BS, United Kingdom, and Novartis Pharma AG, CH-4002, Basel, Switzerland
4 shared publicationsWai Lee
Novartis Institutes for Biomedical Research, 5 Gower Place, London WC1E 6BS, U.K., and Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland
4 shared publicationsM. N. Perkins
3 shared publicationsM.N. Perkins
Sandoz Institute for Medical Research, 5 Gower Place, London WC1E 6BN
3 shared publications
Latest Publications
- 14 July 2007
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (16) , 3851-3856
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A Potent, Orally Bioavailable Human CB1/CB2Dual Agonist with Antihyperalgesic Properties and Restricted Central Nervous System Penetration
Selective activation of peripheral cannabinoid CB1 receptors has the potential to become a valuable therapy for chronic pain conditions as long as central nervous system effects are attenuated. A new class of cannabinoid ligands was rationally designed from known aminoalkylindole agonists and showed good binding and functional activities at human CB1 and CB2 receptors. This has led to the discovery of a novel CB1/CB2 dual agonist, naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (13), which displays good oral bioavailability, potent antihyperalgesic activity in animal models, and limited brain penetration.
- 14 July 2007
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (16) , 3851-3856
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A Potent, Orally Bioavailable Human CB1/CB2Dual Agonist with Antihyperalgesic Properties and Restricted Central Nervous System Penetration
Selective activation of peripheral cannabinoid CB1 receptors has the potential to become a valuable therapy for chronic pain conditions as long as central nervous system effects are attenuated. A new class of cannabinoid ligands was rationally designed from known aminoalkylindole agonists and showed good binding and functional activities at human CB1 and CB2 receptors. This has led to the discovery of a novel CB1/CB2 dual agonist, naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (13), which displays good oral bioavailability, potent antihyperalgesic activity in animal models, and limited brain penetration.
- 20 December 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (2) , 471-474
Identification and Biological Characterization of 6-Aryl-7-isopropylquinazolinones as Novel TRPV1 Antagonists that Are Effective in Models of Chronic Pain
Vanilloid receptor 1 (VR1, TRPV1) is a cation-selective ion channel that is expressed on primary afferent neurons and is upregulated following inflammation and nerve damage. Blockers of this channel may have utility in the treatment of chronic nociceptive and neuropathic pain. Here, we describe the optimization from a high throughput screening hit, of a series of 6-aryl-7-isopropylquinazolinones that are TRPV1 antagonists in vitro. We also demonstrate that one compound is active in vivo against capsaicin-induced hyperalgesia and in models of neuropathic and nociceptive pain in the rat.
- 20 December 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (2) , 471-474
Identification and Biological Characterization of 6-Aryl-7-isopropylquinazolinones as Novel TRPV1 Antagonists that Are Effective in Models of Chronic Pain
Vanilloid receptor 1 (VR1, TRPV1) is a cation-selective ion channel that is expressed on primary afferent neurons and is upregulated following inflammation and nerve damage. Blockers of this channel may have utility in the treatment of chronic nociceptive and neuropathic pain. Here, we describe the optimization from a high throughput screening hit, of a series of 6-aryl-7-isopropylquinazolinones that are TRPV1 antagonists in vitro. We also demonstrate that one compound is active in vivo against capsaicin-induced hyperalgesia and in models of neuropathic and nociceptive pain in the rat.
- 24 April 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (11) , 2160-2172
Nonpeptide Bradykinin B2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally-Active Human Bradykinin B2 Receptor Antagonists
The 1-(2-nitrophenyl)thiosemicarbazide (TSC) derivative, (S)-1-[4-(4-benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]pyrrolidine-2-carboxylic acid {2-[(2-dimethylaminoethyl)methylamino]ethyl}amide (bradyzide; (S)-4), was recently disclosed as a novel, potent, orally active nonpeptide bradykinin (BK) B2 receptor antagonist. The compound inhibited the specific binding of [3H]BK to NG108-15 cell membrane preparations (rodent neuroblastoma-glioma) expressing B2 receptors with a Ki of 0.5 ± 0.2 nM. Compound (S)-4 also demonstrated oral efficacy against Freund's complete adjuvant (FCA)-induced mechanical hyperalgesia in rats with an ED50 value of 0.84 μmol/kg. After we optimized the terminal binding determinants projecting from the TSC framework, we found that it was possible to replace the potentially toxicophoric nitro and divalent sulfur moieties with only a 15-fold loss in binding affinity ((S)-14a). However, bradyzide and its congeners were found to have much lower affinities for cloned human B2 receptors, expressed in Cos-7 cells. The hitherto synthesized TSC series was screened against the human B2 receptor, and the dibenzosuberane (DBS) pharmacophore emerged as the key structural requirement for potency. Incorporation of this group resulted in a series of derivatives ((S)-14d,e and 19b − d) with Ki ranges of 10.7−176 nM in NG108-15 cells (expressing the rodent B2 receptor) and 0.79−253 nM in Cos-7 cells (expressing the human B2 receptor). There was no evidence of agonist activity with any of the nonpeptides in any of the cell lines tested. In vivo, oral administration of compound 19c reversed FCA-induced and turpentine-induced mechanical hyperalgesia in rodents with ED50 values of 0.027 and 0.32 μmol/kg, respectively. The selectivity profiles of compounds (S)-14f and (S)-14 g were also assessed to determine the conformational and/or steric preferences of the double-ring arrangement. The affinity of (S)-14 g for the human B2 receptor suggested that it may be a hydrophobic interaction with the ethane bridge of the DBS moiety that accounts for the increased potency of compounds (S)-14d,e and 19b,c at this receptor, by favoring a binding mode inaccessible to the unsubstituted diphenylmethyl derivative, (S)-4.
- 24 April 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (11) , 2160-2172
Nonpeptide Bradykinin B2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally-Active Human Bradykinin B2 Receptor Antagonists
The 1-(2-nitrophenyl)thiosemicarbazide (TSC) derivative, (S)-1-[4-(4-benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]pyrrolidine-2-carboxylic acid {2-[(2-dimethylaminoethyl)methylamino]ethyl}amide (bradyzide; (S)-4), was recently disclosed as a novel, potent, orally active nonpeptide bradykinin (BK) B2 receptor antagonist. The compound inhibited the specific binding of [3H]BK to NG108-15 cell membrane preparations (rodent neuroblastoma-glioma) expressing B2 receptors with a Ki of 0.5 ± 0.2 nM. Compound (S)-4 also demonstrated oral efficacy against Freund's complete adjuvant (FCA)-induced mechanical hyperalgesia in rats with an ED50 value of 0.84 μmol/kg. After we optimized the terminal binding determinants projecting from the TSC framework, we found that it was possible to replace the potentially toxicophoric nitro and divalent sulfur moieties with only a 15-fold loss in binding affinity ((S)-14a). However, bradyzide and its congeners were found to have much lower affinities for cloned human B2 receptors, expressed in Cos-7 cells. The hitherto synthesized TSC series was screened against the human B2 receptor, and the dibenzosuberane (DBS) pharmacophore emerged as the key structural requirement for potency. Incorporation of this group resulted in a series of derivatives ((S)-14d,e and 19b − d) with Ki ranges of 10.7−176 nM in NG108-15 cells (expressing the rodent B2 receptor) and 0.79−253 nM in Cos-7 cells (expressing the human B2 receptor). There was no evidence of agonist activity with any of the nonpeptides in any of the cell lines tested. In vivo, oral administration of compound 19c reversed FCA-induced and turpentine-induced mechanical hyperalgesia in rodents with ED50 values of 0.027 and 0.32 μmol/kg, respectively. The selectivity profiles of compounds (S)-14f and (S)-14 g were also assessed to determine the conformational and/or steric preferences of the double-ring arrangement. The affinity of (S)-14 g for the human B2 receptor suggested that it may be a hydrophobic interaction with the ethane bridge of the DBS moiety that accounts for the increased potency of compounds (S)-14d,e and 19b,c at this receptor, by favoring a binding mode inaccessible to the unsubstituted diphenylmethyl derivative, (S)-4.
- 13 June 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 421 (3) , 191-199
p38 stress-activated protein kinase inhibitor reverses bradykinin B1 receptor-mediated component of inflammatory hyperalgesia
- 13 June 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 421 (3) , 191-199
p38 stress-activated protein kinase inhibitor reverses bradykinin B1 receptor-mediated component of inflammatory hyperalgesia
- 1 January 2001
- Published by Elsevier in Neuropharmacology
- Vol. 40 (1) , 10-19
mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia
- 1 January 2001
- Published by Elsevier in Neuropharmacology
- Vol. 40 (1) , 10-19
mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia
- 1 January 2001
- Published by Elsevier in Neuropharmacology
- Vol. 40 (1) , 1-9
Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function
- 1 January 2001
- Published by Elsevier in Neuropharmacology
- Vol. 40 (1) , 1-9
Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function
- 12 February 2000
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (5) , 769-771
1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B2 Receptor
- 12 February 2000
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (5) , 769-771
1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B2 Receptor
- 30 January 2000
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (1) , 77-86
Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia
Bradyzide is from a novel class of rodent‐selective non‐peptide B2 bradykinin antagonists (1‐(2‐Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B2 receptor, displacing [3H]‐bradykinin binding in NG108‐15 cells and in Cos‐7 cells expressing the rat receptor with KI values of 0.51±0.18 nM (n=3) and 0.89±0.27 nM (n=3), respectively. Bradyzide is a competitive antagonist, inhibiting B2 receptor‐induced 45Ca efflux from NG108‐15 cells with a pKB of 8.0±0.16 (n=5) and a Schild slope of 1.05. In the rat spinal cord and tail preparation, bradyzide inhibits bradykinin‐induced ventral root depolarizations (IC50 value; 1.6±0.05 nM (n=3)). Bradyzide is much less potent at the human than at the rodent B2 receptor, displacing [3H]‐bradykinin binding in human fibroblasts and in Cos‐7 cells expressing the human B2 receptor with KI values of 393±90 nM (n=3) and 772±144 nM (n=3), respectively. Bradyzide inhibits bradykinin‐induced [3H]‐inositol trisphosphate (IP3) formation with IC50 values of 11.6±1.4 nM (n=3) at the rat and 2.4±0.3 μM (n=3) at the human receptor. Bradyzide does not interact with a range of other receptors, including human and rat B1 bradykinin receptors. Bradyzide is orally available and blocks bradykinin‐induced hypotension and plasma extravasation. Bradyzide shows long‐lasting oral activity in rodent models of inflammatory hyperalgesia, reversing Freund's complete adjuvant (FCA)‐induced mechanical hyperalgesia in the rat knee joint (ED50, 0.84 μmol kg−1; duration of action >4 h). It is equipotent with morphine and diclofenac, and 1000 times more potent than paracetamol, its maximal effect exceeding that of the non‐steroidal anti‐inflammatory drugs (NSAIDs). Bradyzide does not exhibit tolerance when administered over 6 days. In summary, bradyzide is a potent, orally active, antagonist of the B2 bradykinin receptor, with selectivity for the rodent over the human receptor. British Journal of Pharmacology (2000) 129, 77–86; doi:10.1038/sj.bjp.0703012
- 30 January 2000
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (1) , 77-86
Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia
Bradyzide is from a novel class of rodent‐selective non‐peptide B2 bradykinin antagonists (1‐(2‐Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B2 receptor, displacing [3H]‐bradykinin binding in NG108‐15 cells and in Cos‐7 cells expressing the rat receptor with KI values of 0.51±0.18 nM (n=3) and 0.89±0.27 nM (n=3), respectively. Bradyzide is a competitive antagonist, inhibiting B2 receptor‐induced 45Ca efflux from NG108‐15 cells with a pKB of 8.0±0.16 (n=5) and a Schild slope of 1.05. In the rat spinal cord and tail preparation, bradyzide inhibits bradykinin‐induced ventral root depolarizations (IC50 value; 1.6±0.05 nM (n=3)). Bradyzide is much less potent at the human than at the rodent B2 receptor, displacing [3H]‐bradykinin binding in human fibroblasts and in Cos‐7 cells expressing the human B2 receptor with KI values of 393±90 nM (n=3) and 772±144 nM (n=3), respectively. Bradyzide inhibits bradykinin‐induced [3H]‐inositol trisphosphate (IP3) formation with IC50 values of 11.6±1.4 nM (n=3) at the rat and 2.4±0.3 μM (n=3) at the human receptor. Bradyzide does not interact with a range of other receptors, including human and rat B1 bradykinin receptors. Bradyzide is orally available and blocks bradykinin‐induced hypotension and plasma extravasation. Bradyzide shows long‐lasting oral activity in rodent models of inflammatory hyperalgesia, reversing Freund's complete adjuvant (FCA)‐induced mechanical hyperalgesia in the rat knee joint (ED50, 0.84 μmol kg−1; duration of action >4 h). It is equipotent with morphine and diclofenac, and 1000 times more potent than paracetamol, its maximal effect exceeding that of the non‐steroidal anti‐inflammatory drugs (NSAIDs). Bradyzide does not exhibit tolerance when administered over 6 days. In summary, bradyzide is a potent, orally active, antagonist of the B2 bradykinin receptor, with selectivity for the rodent over the human receptor. British Journal of Pharmacology (2000) 129, 77–86; doi:10.1038/sj.bjp.0703012
- 1 January 2000
- Published by Association for Tropical Biology in Biotropica
- Vol. 32 (3)
The Flight Heights of Chalcid Wasps (Hymenoptera, Chalcidoidea) in a Lowland Bornean Rain Forest: Fig Wasps are the High Fliers1
Tropical rain forests are characterized by their rich plant diversity and highly diverse insect faunas containing mainly rare species. Phytophagous and parasitoid insects utilizing such fragmented resources often must travel considerable distances to find suitable hosts. For small, weak-flying insects, entry into the fast-flowing air above the canopy can provide one way by which long-distance dispersal is achieved. Using sticky traps placed at different heights in a lowland rain forest of Borneo, we compared the diurnal and nocturnal flight heights of chalcids, a group of mainly very small parasitoids and phytophages, to determine if the air above the canopy was used for dispersal. Most families were represented throughout the range of trap heights, including those above the general canopy. A higher proportion of individuals were trapped above the canopy at night than during the day. Fig wasps were exceptional in that they were trapped almost entirely above the canopy. They included species associated with host trees that do not fruit in the canopy, suggesting that these short-lived, slow-flying insects actively fly up above the canopy and then use the wind to passively carry them the long distances needed to reach their highly localized and ephemeral hosts. Once the fig wasps detect the species-specific volatiles released by their host figs, they then may fly down into the canopy, where the lower wind speeds would allow them to fly actively upwind to their hosts.
- 1 January 2000
- Published by Association for Tropical Biology in Biotropica
- Vol. 32 (3)
The Flight Heights of Chalcid Wasps (Hymenoptera, Chalcidoidea) in a Lowland Bornean Rain Forest: Fig Wasps are the High Fliers1
Tropical rain forests are characterized by their rich plant diversity and highly diverse insect faunas containing mainly rare species. Phytophagous and parasitoid insects utilizing such fragmented resources often must travel considerable distances to find suitable hosts. For small, weak-flying insects, entry into the fast-flowing air above the canopy can provide one way by which long-distance dispersal is achieved. Using sticky traps placed at different heights in a lowland rain forest of Borneo, we compared the diurnal and nocturnal flight heights of chalcids, a group of mainly very small parasitoids and phytophages, to determine if the air above the canopy was used for dispersal. Most families were represented throughout the range of trap heights, including those above the general canopy. A higher proportion of individuals were trapped above the canopy at night than during the day. Fig wasps were exceptional in that they were trapped almost entirely above the canopy. They included species associated with host trees that do not fruit in the canopy, suggesting that these short-lived, slow-flying insects actively fly up above the canopy and then use the wind to passively carry them the long distances needed to reach their highly localized and ephemeral hosts. Once the fig wasps detect the species-specific volatiles released by their host figs, they then may fly down into the canopy, where the lower wind speeds would allow them to fly actively upwind to their hosts.
- Open Access
- 1 August 1996
- Published by Wiley in British Journal of Pharmacology
- Vol. 118 (8) , 2206-2212
Substance P and capsaicin‐induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors
Substance P (SP) and capsaicin induced a mechanical hyperalgesia when injected into rat knee joints. The NK1 receptor antagonists CP 99994 (10–100 nmol) and RP 67580 (0.1‐1 nmol) blocked the development of, and also reversed, SP‐induced hyperalgesia. Capsaicin (10 nmol)‐induced hyperalgesia was blocked by capsazepine (0.5‐5 nmol). Capsaicin‐induced hyperalgesia was prevented and reversed by the NK1 receptor antagonists CP 99994 (100 nmol) and RP 67580 (1 nmol). The bradykinin B2 receptor antagonist icatibant (5 pmol) blocked the development of both SP and capsaicin‐induced hyperalgesia. Icatibant (100 pmol kg−1, i.v.) also reversed an established SP and capsaicin‐induced hyperalgesia. Both low dose SP (1 nmol) and capsaicin (1 nmol)‐induced hyperalgesia were potentiated by the kininase II inhibitor captopril (100 μg). The B1 receptor antagonists desArg9Leu8‐bradykinin (BK) (0.5‐5 nmol) and desArg10[Hoe 140] (5–50 pmol) only blocked the development of SP‐induced hyperalgesia for 30 min after administration. desArg9Leu8‐BK (10 nmol kg−1 i.v.) did not reverse an established SP‐induced hyperalgesia. Capsaicin‐induced hyperalgesia was blocked by desArg9Leu8‐BK (0.5 nmol) and this antagonist also reversed an established capsaicin‐induced hyperalgesia. Interleukin‐1 receptor antagonist (IL‐1ra 0.1 μg) reduced the development of SP‐induced hyperalgesia up to 4 h after administration, but did not reverse an established hyperalgesia. IL‐1ra (0.1 μg) also blocked the development of and reversed an established capsaicin‐induced hyperalgesia. Indomethacin pretreatment (1 mg kg−1, s.c.) did not reduce the development of either SP‐ or capsaicin‐induced hyperalgesia but following indomethacin‐pretreatment desArg9Leu8‐BK (10 nmol kg−1, i.v.) failed to reverse a capsaicin‐induced hyperalgesia. In conclusion, both SP and capsaicin can induce behavioural hyperalgesia when injected into the knee joint of rats. In addition, blockade of NK1, bradykinin B1, B2 and IL‐1β receptors can substantially modulate this hyperalgesia.
- 1 August 1996
- Published by Wiley in British Journal of Pharmacology
- Vol. 118 (8) , 2206-2212
Open AccessSubstance P and capsaicin‐induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors
Substance P (SP) and capsaicin induced a mechanical hyperalgesia when injected into rat knee joints. The NK1 receptor antagonists CP 99994 (10–100 nmol) and RP 67580 (0.1‐1 nmol) blocked the development of, and also reversed, SP‐induced hyperalgesia. Capsaicin (10 nmol)‐induced hyperalgesia was blocked by capsazepine (0.5‐5 nmol). Capsaicin‐induced hyperalgesia was prevented and reversed by the NK1 receptor antagonists CP 99994 (100 nmol) and RP 67580 (1 nmol). The bradykinin B2 receptor antagonist icatibant (5 pmol) blocked the development of both SP and capsaicin‐induced hyperalgesia. Icatibant (100 pmol kg−1, i.v.) also reversed an established SP and capsaicin‐induced hyperalgesia. Both low dose SP (1 nmol) and capsaicin (1 nmol)‐induced hyperalgesia were potentiated by the kininase II inhibitor captopril (100 μg). The B1 receptor antagonists desArg9Leu8‐bradykinin (BK) (0.5‐5 nmol) and desArg10[Hoe 140] (5–50 pmol) only blocked the development of SP‐induced hyperalgesia for 30 min after administration. desArg9Leu8‐BK (10 nmol kg−1 i.v.) did not reverse an established SP‐induced hyperalgesia. Capsaicin‐induced hyperalgesia was blocked by desArg9Leu8‐BK (0.5 nmol) and this antagonist also reversed an established capsaicin‐induced hyperalgesia. Interleukin‐1 receptor antagonist (IL‐1ra 0.1 μg) reduced the development of SP‐induced hyperalgesia up to 4 h after administration, but did not reverse an established hyperalgesia. IL‐1ra (0.1 μg) also blocked the development of and reversed an established capsaicin‐induced hyperalgesia. Indomethacin pretreatment (1 mg kg−1, s.c.) did not reduce the development of either SP‐ or capsaicin‐induced hyperalgesia but following indomethacin‐pretreatment desArg9Leu8‐BK (10 nmol kg−1, i.v.) failed to reverse a capsaicin‐induced hyperalgesia. In conclusion, both SP and capsaicin can induce behavioural hyperalgesia when injected into the knee joint of rats. In addition, blockade of NK1, bradykinin B1, B2 and IL‐1β receptors can substantially modulate this hyperalgesia.